Position in EXEL
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$443,550
+$81,259 QoQ
Shares Held
8,152
-3.5% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#447
of 751 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GREENWOOD CAPITAL ASSOCIATES LLC holds $17,673,711 across 9 Biotechnology names. EXEL ranks #5 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
13,873 | $8,650,370 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,024 | $5,972,681 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
7,752 | $606,749 | |
| 4 | KRYS |
Krystal Biotech, Inc.
|
1,495 | $555,646 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
8,152 | $443,550 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
773 | $415,062 | |
| 7 | INCY |
Incyte Corp
|
3,319 | $376,241 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
6,121 | $333,839 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $443,550 | 8,152 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $362,291 | 8,447 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $388,465 | 8,863 | Shares | Sole | 2026-01-26 | |
| 2025-09-30 | $400,155 | 9,689 | Shares | Sole | 2025-10-16 | |
| No filing history on record for this holder in this stock. | ||||||